| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Polson AG et al. | Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. | 2009 | Cancer Res. | pmid:19258515 |
| Lewis Phillips GD et al. | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. | 2008 | Cancer Res. | pmid:19010901 |
| Arai MA et al. | Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. | 2008 | Bioorg. Med. Chem. | pmid:18842418 |
| Hull RN et al. | Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. | 1977 | Thromb. Res. | pmid:18812 |
| Bai RL et al. | Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. | 1991 | J. Biol. Chem. | pmid:1874739 |
| Zhao P et al. | Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. | 2008 | Chem. Biol. | pmid:18721757 |
| Stephan JP et al. | Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. | 2008 | Bioconjug. Chem. | pmid:18637680 |
| Ostermann E et al. | Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. | 2008 | Clin. Cancer Res. | pmid:18628473 |
| Taft F et al. | Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. | 2008 | Chembiochem | pmid:18381586 |
| Galsky MD et al. | Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. | 2008 | J. Clin. Oncol. | pmid:18362364 |
| Rodon J et al. | Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. | 2008 | Cancer Chemother. Pharmacol. | pmid:18301896 |
| Ishitsuka K et al. | Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. | 2008 | Br. J. Haematol. | pmid:18279455 |
| Riechelmann H et al. | Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. | 2008 | Oral Oncol. | pmid:18203652 |
| Goh S et al. | An integrative expression vector for Actinosynnema pretiosum. | 2007 | BMC Biotechnol. | pmid:17956638 |
| Snipes CE et al. | The ansacarbamitocins: polar ansamitocin derivatives. | 2007 | J. Nat. Prod. | pmid:17892263 |
| Chari RV | Targeted cancer therapy: conferring specificity to cytotoxic drugs. | 2008 | Acc. Chem. Res. | pmid:17705444 |
| Ma J et al. | New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum. | 2007 | Arch. Pharm. Res. | pmid:17679541 |
| Reddy JA et al. | Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. | 2007 | Cancer Res. | pmid:17616697 |
| Li Y et al. | Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site. | 1992 | Biochem. Pharmacol. | pmid:1739410 |
| Meyer A et al. | Chemoenzymatic approaches toward dechloroansamitocin P-3. | 2007 | Org. Lett. | pmid:17378571 |